Cargando…

Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study

BACKGROUND AND OBJECTIVES: Natalizumab reduces the relapse rate and magnetic resonance imaging activity in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). So far the influence of natalizumab on cognitive functions and fatigue in MS remains uncertain. The aim of this prospective, open-la...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iaffaldano, Pietro, Viterbo, Rosa Gemma, Paolicelli, Damiano, Lucchese, Guglielmo, Portaccio, Emilio, Goretti, Benedetta, Direnzo, Vita, D'Onghia, Mariangela, Zoccolella, Stefano, Amato, Maria Pia, Trojano, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338465/ https://www.ncbi.nlm.nih.gov/pubmed/22558238 http://dx.doi.org/10.1371/journal.pone.0035843

Ejemplares similares

Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients
por: Zoccolella, Stefano, et al.
Publicado: (2012)

Gender differences in safety issues during Fingolimod therapy: Evidence from a real‐life Relapsing Multiple Sclerosis cohort
por: Manni, Alessia, et al.
Publicado: (2017)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016)

Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort
por: Manni, Alessia, et al.
Publicado: (2019)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

Magnetoencephalography and High-Density Electroencephalography Study of Acoustic Event Related Potentials in Early Stage of Multiple Sclerosis: A Pilot Study on Cognitive Impairment and Fatigue
por: Paolicelli, Damiano, et al.
Publicado: (2021)

Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis
por: Trojano, Maria, et al.
Publicado: (2012)

Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience
por: Guerra, Tommaso, et al.
Publicado: (2022)

Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate
por: Bollo, Luca, et al.
Publicado: (2022)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients
por: Biasi, Madia M., et al.
Publicado: (2023)

Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis
por: Rossi, Francesca, et al.
Publicado: (2012)

Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients
por: Paolicelli, Damiano, et al.
Publicado: (2022)

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
por: Bollo, Luca, et al.
Publicado: (2020)

Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy
por: Ruggieri, Maddalena, et al.
Publicado: (2020)

Proteomic Profiling in Multiple Sclerosis Clinical Courses Reveals Potential Biomarkers of Neurodegeneration
por: Liguori, Maria, et al.
Publicado: (2014)

The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population
por: Goretti, Benedetta, et al.
Publicado: (2014)

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)

A rare association between multiple sclerosis and Charcot‐Marie‐Tooth type 1B
por: Cortese, Rosa, et al.
Publicado: (2016)

A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review
por: Parisi, Mosè, et al.
Publicado: (2020)

Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsing–Remitting Multiple Sclerosis
por: Kunkel, Annett, et al.
Publicado: (2015)

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis
por: Prosperini, Luca, et al.
Publicado: (2019)

Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial
por: Simone, Marta, et al.
Publicado: (2018)

A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis
por: Simone, Marta, et al.
Publicado: (2021)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study
por: Pastò, Luisa, et al.
Publicado: (2012)

The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Can Protect Against Cognitive Impairment in Multiple Sclerosis
por: Portaccio, Emilio, et al.
Publicado: (2021)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients
por: Niccolai, Claudia, et al.
Publicado: (2015)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics
por: Signorile, Anna, et al.
Publicado: (2020)

Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness
por: Penner, Iris-Katharina, et al.
Publicado: (2015)

Cognitive Issues in Pediatric Multiple Sclerosis
por: Portaccio, Emilio, et al.
Publicado: (2021)

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study
por: Pecori, Chiara, et al.
Publicado: (2014)

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
por: Giannini, Marta, et al.
Publicado: (2012)

PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels
por: De Rasmo, Domenico, et al.
Publicado: (2020)

Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors
por: Amato, Maria Pia, et al.
Publicado: (2019)

Correction: Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors
por: Amato, Maria Pia, et al.
Publicado: (2019)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_suma124vps4ank8l3qnj1pt9u8